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Abstract
Background: Hepatitis B virus (HBV) is divided into 8 definite (A-H) and 2 putative (I, J) genotypes that show a
geographical distribution. HBV genotype G, however, is an aberrant genotype of unknown origin that demonstrates
severe replication deficiencies and very little genetic variation. It is often found in co-infections with another HBV
genotype and infection has been associated with certain risk groups such as intravenous drug users and men
having sex with men (MSM). We aimed to estimate the prevalence of HBV-G in the Netherlands by analysing
samples from HBV-positive patients visiting the Academic Medical Center in Amsterdam.
Methods: Ninety-six HBV-infected patients, genotyped as HBV-A or HBV-G infected, were retrieved from the clinical
database. Blood plasma samples were analysed with a newly-developed real-time PCR assay that detects HBV-A and
HBV-G. For three patients, the HBV plasma viral load (pVL) of both genotypes was followed longitudinally. In
addition, three complete genomes of HBV-G were sequenced to determine their relationship to global HBV-G
strains.
Results: Ten HBV-G infections were found in the selected Dutch patients. All concerned HIV-1 infected males with
HBV-A co-infection. Dutch HBV-G strains were phylogenetically closely related to reference HBV-G strains.
Conclusions: In this study, HBV-G infection in the Netherlands is found exclusively in HIV-1 infected men as
co-infection with HBV-A. A considerable percentage (37%) of men infected with HBV and HIV-1 are actually
co- infected with two HBV genotypes.
Background
Hepatitis B virus (HBV), the prototype member of the
Hepadnaviridae, can cause chronic hepatitis, cirrhosis and
ultimately hepatocellular carcinoma. HBV is currently di-
vided into eight confirmed genotypes that differ >8% from
each other at the nucleotide level: A to H (for a review,
see: [1]). In addition, a novel genotype I has been reported
from South-East Asia [2-5] and a candidate tenth geno-
type J was suggested [6]. Most genotypes can be split into
subgenotypes that differ >4% from each other, such as
HBV-A1 and HBV-A2 [7]. HBV-A2 is the most prevalent
HBV variant in Western Europe and North America [7].
HBV genotype G (HBV-G), originally described as a mu-
tated HBV variant that emerges during chronic HBV in-
fection [8,9], was recognized as a separate genotype in
2000 [10]. HBV-G is distinct from other HBV genotypes
in having a 36-nucleotide insertion at the 5′ end of the
core protein gene, which adds 12 amino acids to the pro-
tein and interferes with core protein expression and virion
secretion [11-13]. In addition, one or two stopcodons are
usually present in the precore region that preclude HBeAg
expression [10,14]. Altogether, these characteristics ham-
per virus replication and make HBV-G mono-infection a
rarely observed event [14-16]. Apparently, HBV-G replica-
tion can be rescued by co-infection with another HBV
genotype, and such dual infections have been observed re-
peatedly with HBV genotype A in Japan [17,18], the USA
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[19,20], Spain [21] and Canada [22], with HBV genotypes
A, C or D in Germany [23,24], with HBV genotype H in
Mexico [25], and with HBV genotype F in Argentina [26].
In fact, rescue by another genotype can be very effective,
even to the point where HBV-G outcompetes the co-
infecting strain [9,17,19]. This phenomenon has also been
observed in humanized mouse models [27,28]. Infections
with HBV-G are especially prevalent in specific risk
groups such as human immunodeficiency virus type 1
(HIV-1) infected men having sex with men (MSM) and
intravenous drug users [18,21,22,25,26,29-31]. HBV-G
strains isolated worldwide show very little genetic vari-
ation compared to other HBV genotypes [10]. There are
indications that mixed HBV infections that include an
HBV-G strain are associated with increased liver fibrosis
[27,28,30], suggesting that patients infected with HBV-G
should be monitored more closely. Also, response to anti-
viral treatment has been reported to be less effective in pa-
tients co-infected with HBV-G as compared to single
genotype infections [23].
The prevalence of HBV-G infections in most countries
in northern Europe, including the Netherlands, is not
known. Therefore, we determined the occurrence of
HBV-G infections and its association with HBV-A in pa-
tients visiting our academic hospital in Amsterdam, the
Netherlands during 2000-2011. HBV-A is the most
prevalent, endemic HBV genotype in the Netherlands
and is found especially among MSM [32]. In addition,
we determined the longitudinal plasma viral load (pVL)
changes of HBV in genotypes A and G in three dually
infected patients. The complete genomes of three HBV
genotype G strains were sequenced to analyse their gen-




A total of 1674 patients tested HBsAg positive in the
AMC (Amsterdam, the Netherlands) during 2000-2011,
of which 1008 were also tested for HIV-1 infection
(HBV tests requested from outside the AMC, but per-
formed here were not included in the numbers). Of
those 1008 HBV positive patients, 211 were found to be
also HIV-positive. Patients receiving anti-HBV treatment
in whom therapy failure was observed and drug resist-
ance was thus suspected (N = 343), HBV genomic frag-
ments were amplified, sequenced, genotyped and analysed
for drug-resistance mutations. For this study, we se-
lected AMC patients from the database of the AMC
Laboratory of Clinical Virology (Department of Medical
Microbiology) that previously were found to be infected
with HBV genotype A or G. HBV genotyping was done
with an in-house sequencing assay. The Laboratory of
Clinical Virology participates in the Quality Control for
Molecular Diagnostics Hepatitis B virus Genotype EQA
Programme [33] to ensure adequate performance of
this genotyping assay. A total of 96 patient entries met
these criteria and had sample availability; 91 had been
diagnosed as HBV genotype A and 5 as HBV genotype
G. Twenty-seven were HIV-positive (all males), 54 were
HIV-negative and 15 had an unknown HIV status. In
total, sixty-nine patients were male, and 27 were fe-
male. Of the 69 included men, 25 originated from the
Netherlands; the others were from Suriname (N = 11),
Africa (N = 8), other European countries (N = 5), or of
unknown or other origin (N = 20). Of the 27 female pa-
tients, 6 were from the Netherlands, 15 from Suriname,
4 from Africa, and for 2 the country of origin was
unknown.
Real-time PCR assay
Viral DNA was isolated from blood plasma samples
with the QIAamp UltraSens Virus Kit (QIAGEN, the
Netherlands). Single-tube real-time PCR reactions that
specifically quantify HBV genotype A or G DNA were
developed in the HBV X-protein gene and analysed on an
ABI PRISM® 7000 Sequence Detection System (Applied
Biosystems, Foster City, CA, USA) using the primers and
probes shown in Table 1. Primers and probes were highly
specific for the targeted HBV genotype (either A or G).
Cross-reactivity was not detected as the primers and
probes were able to amplify 5 copies of the targeted geno-
type in a background of up to 108 copies of the non-
targeted genotype. All subgenotypes of HBV-A can be
quantified with this assay. The lower limit of detection is 5
copies per reaction (= 1000 copies/ml).
HBV-G genome sequencing
HBV genotype G genome fragments were amplified
from viral DNA isolated from plasma samples and dir-
ectly sequenced with the BigDye Terminator cycle se-
quencing kit (Applied Biosystems, Foster City, CA,





5'HBV-A-TM3_2 1585-1606 TTC GCT TCA CCT CTG CAC GTT G




1636-1613 ATC TGA TGG GCG TTC ACG GTG
GTC
5'HBV-G-TM3_2 1585-1606 TTC GCT TCA CCT CTG CAC GTT A




1636-1613 ATG ATG AGA GGT GTT CAT GGC
GGT T
*Numbering starting at the EcoR1 site.
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USA). Electrophoresis and data collection were per-
formed on an ABI PRISM 3100 genetic analyser (also
from Applied Biosystems). Sequences were assembled
with CodonCode Aligner [34], and aligned with refer-
ence HBV sequences from the NCBI nucleotide database
[35] using ClustalW implemented in BioEdit Sequence
Alignment Editor version 7.0.9 [36]. GenBank accession
numbers for the full-length genotype G sequences are:
KF767450, KF767451, and KF767452.
Ethics
No specific approval by the Institutional Review Board
(IRB) of the Academic Medical Center (AMC) of the
University of Amsterdam was needed for this study in
the Netherlands, because the body materials for this
study were collected under medical treatment, and can
be used for further scientific research when the patients
have given consent and samples are analysed anonym-
ously, as was the case here (Code of Conduct as imple-
mented by the Committee on Regulation of Research
COREON of the Netherlands Epidemiological Society
and the Dutch Federation of Biomedical Scientific Soci-
eties that is followed by the IRB of the AMC).
Results
Prevalence of HBV-A and -G in Amsterdam
The prevalence of HBV genotypes as determined by the
Laboratory of Clinical Virology in HBV-infected patients
visiting the AMC is shown in Figure 1. Genotypes D
(29%) and A (27%) were the most prevalent, followed by
genotypes E (16%), C (15%) and B (12%). Genotype F or
G infections are uncommon (≤ 1%).
A total of 96 patients with HBV infection genotype A
or G infection for whom samples were available were
assessed for the presence of single (A or G) or A/G dual
HBV infection with a single-tube real-time PCR assay
that specifically quantifies these genotypes. Patient char-
acteristics and results are summarized in Table 2. All fe-
male patients (N = 27) were found to be singly infected
with HBV-A. Of the 69 male patients, 55 were infected
with HBV-A only, but 10 were dually infected with both
HBV-A and -G. According to the clinical database all 10
dual infected patients were infected with the HBV sub-
genotype A2. In four male patients, the HBV pVL was
below the detection limit of the assay. None of the pa-
tients exhibited a single infection with HBV-G; all 5 pa-
tients previously diagnosed as HBV genotype G also
carried genotype A. Five patients previously diagnosed
as genotype A also carried genotype G. Strikingly, all ten
dually HBV-A/G infected patients were also infected
with HIV-1. In contrast, none of the HIV-1 negative pa-
tients (42 males and 27 females) were dually HBV in-
fected. So, HBV-A/G dual infection is significantly
associated with HIV-1 infection (two-tailed Fisher’s exact
test, p < 0.0001). In total, 37% of HBV/HIV-1 infected
patients harboured two HBV genotypes. All ten dually
HBV infected patients were HBeAg positive at the time
of testing with the AxSYM® HBe Assay (Abbott Diagnos-
tics, Lake Forest, Ill, USA), suggestive of infection with a
precore protein producing strain [19], such as HBV-A
[21]. The majority of HIV-1 infected males were of
Dutch ethnicity (13/23), with an equal distribution be-
tween those singly (7/13) or dually HBV (6/10) infected.
For the other HIV-1 infected patients the origin was ei-
ther unknown (4/23) or varied widely (6/23, from the
Dominican Republic, Ecuador, Dutch Antilles, Ethiopia,
and Germany). Of the HBV-A/G dually infected pa-
tients, five had unknown risk factors for infection, 1 re-
ported heterosexual contacts as a risk factor, and four
were labelled as MSM in the database.
Figure 1 Percentages of HBV genotypes A-G in HBV-infected patients from Amsterdam. HBV genotypes were determined by the
Laboratory of Clinical Virology of the AMC (Amsterdam, the Netherlands) during 2000-2011.
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Thus, HBV-G infection in Dutch patients is strongly
associated with HBV-A and HIV-1 co-infection, which
likely explains the male-specificity in this analysis, as the
majority of HIV-1 infected patients in the Netherlands
are male (80% in 2011), of which 73% belong to the
MSM risk group [37]. These results suggest that HBV-G
is primarily circulating among MSM in the Netherlands.
To assess the possibility that both HBV-G and HIV-1
circulate in a certain subgroup of patients, as well as in-
vestigating a potential simultaneous transmission of both
viruses we analysed HIV-1 polymerase sequences that
were available for 6 out 10 HIV-1/HBV-A/G infected pa-
tients and 10 HIV-1/HBV-A2 infected patients that were
not infected with HBV-G. A phylogenetic tree was gen-
erated of these 16 sequences plus reference sequences of
HIV-1 subtypes A-K with the neighbour-joining option
in MEGA5 based upon a Kimura 2-parameter distance
matrix [38]. The NJ tree suggested no significant rela-
tionship between the HIV-1 polymerase sequences of
the 6 HBV-A/G dual infected patients (not shown) sug-
gesting that transmission of HIV-1 and HBV-G are inde-
pendent events.
Complete HBV-G genome analysis
To investigate whether HBV-G strains circulating in the
Netherlands are similar to global HBV-G strains, the
DNA genome of three virus isolates (from patients 7, 23
and 27, all of Dutch ethnicity) were amplified and com-
pletely sequenced. The sequences demonstrated the
characteristic 36-nucleotide insertion at the 5′ end of
the core protein gene and two stopcodons in the precore
region that preclude HBeAg expression. Also, a fourth,
but incompletely sequenced HBV-G genome from pa-
tient 26 (originating from the Dominican Republic, but
infected in the Netherlands, where he presented with an
acute HBV infection) showed high sequence similarity
with the other Dutch strains (not shown). HBV-G strains
of patients 7 and 27 were closely related to each other
and to an HBV-G strain originating from a Dutch blood
donor with a HBV-G mono-infection [14]. The virus
isolates of both patients showed resistance mutations
against 3TC in the RT region (L180M and M204V).
All three completely sequenced Dutch HBV-G strains
clustered with HBV-G reference sequences in a phylo-
genetic analysis (Figure 2). Genetic distances between
the Dutch HBV-G genomes and reference HBV-G se-
quences were extremely low, and ranged between 0.002-
0.008 for the full-length sequences. This is in line with
the low genetic diversity of less than 0.5% detected for
all HBV-G strains isolated worldwide [39].
For the other 7 patients, a 359 nucleotide fragment
spanning the precore/core region of HBV-G was ampli-
fied and sequenced. All 7 isolates contained the typical
36-nucleotide insertion as well as the two stopcodons,
and clustered with HBV-G sequences.
HBV-A and -G plasma viral load
For three HBV-A/G dually infected patients (nos. 7, 12
and 23), serial blood plasma samples were available for a
longitudinal analysis. In all three patients, both geno-
types were already present in the first available sample,
so that the order of infection could not be established. A
longitudinal analysis of the pVL of each HBV genotype
was performed with the real-time PCR assay (Figure 3).
All three patients were also HIV-1 infected, and treated
with antiretroviral therapy, including lamivudine (3TC)
and tenofovir (TDF) that target both the HIV-1 and the
HBV RT enzymes. In general, the pVL of HBV-A and
HBV-G follow a similar course in these patients, increas-
ing or decreasing in parallel.
In patient 7, the HBV-G pVL exceeded the HBV-A
pVL considerably (>105 difference) at all time-points
over a 4-year period (Figure 3A). The HBV-A and HIV-1
pVL decreased significantly after the start of an ART
regimen containing 3TC in 2001, and remained close to
or below the detection limit of the assay afterwards for
HBV-A (Figure 3A). 3TC drug resistance occurred in
the HBV-G strain, and its pVL rebounded after an initial
drop. Subsequent initiation of TDF treatment (in
addition to 3TC) resulted in a significant decrease in the
HBV-G pVL.
In patient 12, the HBV-G pVL exceeded the HBV-A
pVL at least tenfold over a 42 month period, except in
the first sample measured (Figure 3B). A period without
ART resulted in an increase in HBV pVL of both geno-
types that decreased again with the restart of ART that
included TDF (Figure 3B).
In patient 23, the pVL of the two genotypes was com-
parable over an 8-year period, despite dramatic fluctua-
tions due to therapy changes (Figure 3C). The HBV-A
and -G pVL also decreased sharply with the start of an
ART regimen that contained both 3TC and TDF. How-
ever, mutations associated with 3TC resistance (L180M
and M204V) developed three years later in both
Table 2 Patient characteristics and results
Gender N HIV-1 status HBV real-time PCR
Male 69 Negative: N = 32 HBV-A: N = 55
Positive: N = 27 HBV-A + HBV-G: N = 10
Unknown: N = 10 Undetectable: N = 4
Female 27 Negative: N = 22 HBV-A: N = 27
Positive: N = 0 HBV-A + HBV-G: N = 0
Unknown: N = 5 Undetectable: N = 0
Total 96 Negative: N = 54 HBV-A: N = 82
Positive: N = 27 HBV-A + HBV-G: N = 10
Unknown: N = 15 Undetectable: N = 4
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genotypes. A regimen containing TDF was subsequently
installed, which lowered both HBV pVLs to just above
the detection limit of the assay.
Discussion
In a population of 96 HBV-infected patients visiting our
academic hospital in Amsterdam that had been geno-
typed to harbour HBV-A or HBV-G, 10 HBV-A/G dual
infections were detected. All 10 HBV-G infections con-
cerned men that were also infected with HIV-1. Studies
from other countries report a similar association of
HBV-G infection with HIV-infection and with the MSM
risk group [22,25,26,30,31]. In our study, only four HBV-
A/G infected patients could be positively identified as
MSM, for five others the risk factor was not stated. But
as HBV-A is largely spreading in MSM (as is HIV-1) in
the Netherlands; their HBV-G infection is most likely
also due to homosexual contacts.
In contrast to the first report of HBV-G in the
Netherlands that occurred as a mono-infection, the
HBV-G infections detected in this study all represent
co-infections with HBV-A. The initial mono-infection
occurred in a Dutch male blood donor who denied risk
factors for HBV infection, suggesting that HBV-G is also
present outside the MSM risk group [14]. However,
drug-resistance mutations were present in this HBV-G
isolate, implying that the strain was most likely transmit-
ted from an ART-treated individual.
HBV-G infections are mainly noticeable after infection
with a “helper” HBV strain, here genotype A, and espe-
cially during HIV-1 co-infection that decreases HBV
immune control and increases HBV replication [40].
HBV-G mono-infected patients have been reported to
be HBeAg negative, variably HBsAg positive (2 out of 3
cases), while HBcAb and HBsAb levels can be inconsist-
ent and/or delayed [14-16]. So, it is not always easy to
Figure 2 Phylogenetic analysis of full-length HBV sequences. The neighbour-joining tree was generated with the MEGA5 software package
[38] and shows the relationship between three novel, full-length HBV-G strains from the Netherlands (indicated by red circles) and reference
sequences of HBV genotypes A1, A2, C, D1, D2 and G obtained from the NCBI nucleotide database [35]. Distances were estimated with the
Kimura 2-parameter method, and bootstrap resampling was done with 1000 replicates. The accession number of the reference sequences is
indicated together with the HBV genotype.
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recognize an HBV-G mono-infected patient as being
HBV positive, especially in a routine diagnostic setting,
and these patients might not have been included in the
current study selection. It would be interesting to exam-
ine HIV-1 infected HBV-negative MSM for HBV-G
mono-infection, as both viruses are circulating in this
risk group. The newly-developed real-time PCR assay
has a detection limit of 5 copies per reaction, enabling
the detection of the low viral DNA levels as observed in
HBV-G mono-infection.
Full-length genome sequencing indicated that the
newly characterized Dutch HBV-G strains are closely re-
lated to reference HBV-G strains isolated around the
world. They all contained the genome peculiarities asso-
ciated with HBV-G, e.g. the 36-nucleotide insertion at
the 5′ end of the core protein gene and two stopcodons
in the precore region, as did isolates from 7 other pa-
tients. This again indicates that HBV-G has no specific
geographical distribution as is the case for the other
HBV genotypes.
For three patients, longitudinal blood plasma samples
were available. Those samples were analysed with the
real-time PCR assay to measure the relative contributions
of each genotype to the pVL. In one patient (no. 23),
HBV-A and HBV-G replicated at a similar level. In the
other two patients (no. 7 and no. 12), the HBV-G pVL
exceeded the HBV-A pVL at least 10 times, in line with
other reports [9,17,19]. The increased HBV-G load in the
presence of a helper strains is also in line with the results
from humanized mouse models [27,28]. In all three cases,
the patients were already infected with both HBV geno-
types and HIV-1 at the first available sampling time, so
that the order of infection cannot be determined. It is pos-
sible that the infections occurred simultaneously, as 37%
of the Dutch HIV-1/HBV-infected MSM were found to be
co-infected with HBV-A and HBV-G, and could thus
transmit multiple HBV strains simultaneously. However,
in the dual HBV-A/G infections described here, the HBV-
G pVL exceeds the HBV-A pVL at least 10 times at most
time points, so it is likely that HBV-G has a better chance
to be transmitted. This finding of a much increased HBV-
G pVL in A/G dual versus mono-infections could also
explain why 5 patients were determined as being singly
Figure 3 Longitudinal analysis of the HBV-A and -G pVL in three
male HIV-1 infected patients. Panel A = patient 7; panel B = patient
12; panel C = patient 23. The HIV-1 pVL is indicated with red bars;
numbers in red are HIV-1 copies/ml. ART regimens are shown below
the graphs. Abbreviations: 3TC = lamivudine; ABC = abacavir; ATV =
atazanavir; d4T = stavidine; DRV = darunavir (boosted with RTV);
EFV = efavirenz; FTC = emtricitabine; IDV = indiniavir; NVP = nevira-
pine; RTV = ritonavir; TDF = tenofovir. 3TC and TDF are also effective
against HBV.
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infected with HBV-G using the clinical HBV genotyping
assay.
Conclusions
The prevalence of HBV genotype G in the Netherlands
was investigated using real-time PCR assays. HBV-G in-
fection was found in 10/96 individuals previously identi-
fied as infected with HBV genotype A or G. These 10
patients were all HIV-1 infected men that were also in-
fected with a HBV genotype A strain, more specifically the
HBV-A2 genotype that is endemic in the Netherlands.
These findings suggest a strong association of HBV-G in
the Netherlands with the HIV-1 infected male risk group,
as has been reported from other countries.
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